Biogen (BIIB) PT Raised to $369 at Morgan Stanley
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $215.50 -1.62%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 9 | New: 26
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 9 | New: 26
Join SI Premium – FREE
Morgan Stanley raised its price target on Biogen (NASDAQ: BIIB) to $369.00 (from $365.00) while maintaining a Overweight rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Securitize Corp (SECZ) PT Raised to $12 at StoneX on 'Innovation Exemption'
- Envista Holdings Corp. (NVST) PT Lowered to $27 at UBS, Neutral Rating Maintained
- Trip.com Group Ltd (9961:HK) (TCOM) PT Lowered to HK$490 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
